J Cancer 2020; 11(2):374-387. doi:10.7150/jca.31640 This issue

Review

TRPV6 as A Target for Cancer Therapy

John M. Stewart

Soricimed Biopharma Inc. 18 Botsford Street, Moncton, NB, Canada, E1C 4W7

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Stewart JM. TRPV6 as A Target for Cancer Therapy. J Cancer 2020; 11(2):374-387. doi:10.7150/jca.31640. Available from https://www.jcancer.org/v11p0374.htm

File import instruction

Abstract

Two decades ago a class of ion channels, hitherto unsuspected, was discovered. In mammals these Transient Receptor Potential channels (TRPs) have not only expanded in number (to 26 functional channels) but also expanded the view of our interface with the physical and chemical environment. Some are heat and cold sensors while others monitor endogenous and/or exogenous chemical signals. Some TRP channels monitor osmotic potential, and others measure cell movement, stretching, and fluid flow. Many TRP channels are major players in nociception and integration of pain signals. One member of the vanilloid sub-family of channels is TRPV6. This channel is highly selective for divalent cations, particularly calcium, and plays a part in general whole-body calcium homeostasis, capturing calcium in the gut from the diet. TRPV6 can be greatly elevated in a number of cancers deriving from epithelia and considerable study has been made of its role in the cancer phenotype where calcium control is dysfunctional. This review compiles and updates recent published work on TRPV6 as a promising drug target in a number of cancers including those afflicting breast, ovarian, prostate and pancreatic tissues.

Keywords: TRPV6, calcium, cancer, prostate, breast, pancreas.